Welcome to our dedicated page for Immunic news (Ticker: IMUX), a resource for investors and traders seeking the latest updates and insights on Immunic stock.
Immunic Inc (IMUX) is a clinical-stage biopharmaceutical company pioneering oral therapies for chronic inflammatory and autoimmune diseases. This page serves as the definitive source for Immunic's latest developments, including clinical trial progress, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on key programs like IMU-838 for multiple sclerosis, IMU-935 for psoriasis, and IMU-856 targeting gastrointestinal disorders. Our news collection covers essential updates including FDA communications, trial result publications, and scientific conference presentations.
Bookmark this page to efficiently track Immunic's progress in advancing selective immunomodulation therapies while maintaining accessibility for both professional investors and those new to understand the company's pipeline.
Immunic, Inc. (IMUX) announces publication of data from its phase 2 EMPhASIS trial of vidofludimus calcium in patients with relapsing-remitting multiple sclerosis (RRMS) in Neurology® Neuroimmunology & Neuroinflammation. The study shows that vidofludimus calcium suppresses MRI lesions by 76% to 78% compared to placebo, reduces disability worsening events, and displays a dose-dependent effect in RRMS patients. Immunic continues with phase 3 ENSURE trials in relapsing MS and phase 2 CALLIPER trial in progressive MS.
FAQ
What is the current stock price of Immunic (IMUX)?
What is the market cap of Immunic (IMUX)?
